CN106693034A - Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding - Google Patents
Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding Download PDFInfo
- Publication number
- CN106693034A CN106693034A CN201710189084.1A CN201710189084A CN106693034A CN 106693034 A CN106693034 A CN 106693034A CN 201710189084 A CN201710189084 A CN 201710189084A CN 106693034 A CN106693034 A CN 106693034A
- Authority
- CN
- China
- Prior art keywords
- parts
- amnion
- vacuum
- freeze
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000001954 sterilising effect Effects 0.000 title claims description 7
- 230000000740 bleeding effect Effects 0.000 title abstract description 3
- 210000001691 amnion Anatomy 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 10
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 241000205585 Aquilegia canadensis Species 0.000 claims description 3
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 3
- 240000007551 Boswellia serrata Species 0.000 claims description 3
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 3
- 244000020518 Carthamus tinctorius Species 0.000 claims description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 3
- 240000007311 Commiphora myrrha Species 0.000 claims description 3
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 3
- 239000004863 Frankincense Substances 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000001728 nano-filtration Methods 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 241000050051 Chelone glabra Species 0.000 claims 1
- 240000005250 Chrysanthemum indicum Species 0.000 claims 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 1
- 240000004980 Rheum officinale Species 0.000 claims 1
- 235000008081 Rheum officinale Nutrition 0.000 claims 1
- 229940030225 antihemorrhagics Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 230000000025 haemostatic effect Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 13
- 206010052428 Wound Diseases 0.000 abstract description 11
- 230000035876 healing Effects 0.000 abstract description 6
- 230000002439 hemostatic effect Effects 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000029663 wound healing Effects 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 102000004266 Collagen Type IV Human genes 0.000 description 3
- 108010042086 Collagen Type IV Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 241000132012 Atractylodes Species 0.000 description 2
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008971 epithelial apoptosis Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种无污染的杀菌止血医用敷料的制备方法,采用分阶段的真空冷冻干燥技术处理羊膜并浸渍中药提取物,制备出一种有效的杀菌止血的医用敷料,可以广泛应用于各种不同程度的创面的治疗,与现有技术相比,本发明制备得到的医用敷料止血止痛、促进愈合,并且对人体无副作用,使用安全。本发明的制备方法简单易行,成本低,无污染。The invention relates to a method for preparing a non-polluting bactericidal and hemostatic medical dressing. The amniotic membrane is processed by staged vacuum freeze-drying technology and soaked in traditional Chinese medicine extracts to prepare an effective bactericidal and hemostatic medical dressing, which can be widely used in various Compared with the prior art, the medical dressing prepared by the invention stops bleeding, relieves pain, promotes healing, has no side effects on human body, and is safe to use for the treatment of wounds in different degrees. The preparation method of the invention is simple, easy to implement, low in cost and pollution-free.
Description
本发明是申请号:2015104682485,申请日:2015-08-03,发明名称:一种杀菌止血的医用敷料的制备方法的分案申请。The present invention is a divisional application of application number: 2015104682485, application date: 2015-08-03, and invention name: a preparation method of a bactericidal and hemostatic medical dressing.
技术领域technical field
本发明属于医用材料领域,具体涉及一种无污染的杀菌止血医用敷料的制备方法。The invention belongs to the field of medical materials, in particular to a method for preparing a non-polluting bactericidal and hemostatic medical dressing.
背景技术Background technique
在人们日常生活中,烧伤、烫伤时常发生,造成各种深度不同的创面,并极易造成感染,导致各种并发症,因此用于该领域的有效的医用敷料的研制是急需解决的问题。羊膜由于自身独有的特性受到国内外学者关注,羊膜从细胞滋养层衍化而来,是胚胎双层膜的内层,由上皮细胞层,基底膜和无血管基质组成,羊膜中包含多种胶原蛋白以及层粘连蛋白、纤连蛋白、糖胺聚糖、透明质酸等。正是这些活性物质的存在,可以促进上皮细胞的黏附移行,诱导上皮分化,防止上皮凋亡,使得羊膜充当一种“可移植的基底膜”来促进上皮化。此外,羊膜基质中还包含有很多生长因子,比如神经生长因子(NGF),肝细胞生长因子(HGF),角质细胞生长因子(KGF),转化生长因子-α(TGF-α),转化生长因子-β1(TGF-β1),表皮生长因子(EGF),碱性成纤维细胞生长因子(bFGF)等等,能够促进眼表上皮化、减轻炎性反应、抑制纤维组织增生和新生血管形成。因此,近年来羊膜在眼表重建中的应用备受瞩目。In people's daily life, burns and scalds often occur, causing wounds with different depths, and are very easy to cause infection and various complications. Therefore, the development of effective medical dressings for this field is an urgent problem to be solved. Due to its unique characteristics, the amniotic membrane has attracted the attention of scholars at home and abroad. The amniotic membrane is derived from the cytotrophoblast, which is the inner layer of the double membrane of the embryo. It is composed of epithelial cell layer, basement membrane and avascular matrix. The amniotic membrane contains a variety of collagens protein and laminin, fibronectin, glycosaminoglycan, hyaluronic acid, etc. It is the presence of these active substances that can promote the adhesion and migration of epithelial cells, induce epithelial differentiation, and prevent epithelial apoptosis, making the amnion a "transplantable basement membrane" to promote epithelialization. In addition, amnion stroma also contains many growth factors, such as nerve growth factor (NGF), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), transforming growth factor-α (TGF-α), transforming growth factor -β1 (TGF-β1), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), etc., can promote ocular surface epithelialization, reduce inflammatory response, inhibit fibrous tissue proliferation and angiogenesis. Therefore, the application of amniotic membrane in ocular surface reconstruction has attracted much attention in recent years.
发明内容Contents of the invention
本发明的目的在于利用羊膜与特定中草药结合共同制备出一种有效的杀菌止血的医用敷料,以解决现有技术中存在的上述问题。The purpose of the present invention is to combine amniotic membrane and specific Chinese herbal medicine to prepare an effective bactericidal and hemostatic medical dressing, so as to solve the above-mentioned problems in the prior art.
本发明采用如下技术方案:一种无污染的杀菌止血医用敷料的制备方法,包括以下步骤:The present invention adopts the following technical scheme: a preparation method of a pollution-free bactericidal and hemostatic medical dressing, comprising the following steps:
(1)消毒杀菌:用生理盐水清洗羊膜后,浸泡于过氧化氢水溶液中2-3h,然后用水清洗干净;将消毒后的羊膜浸泡于含有抗生素的水溶液2~3h;(1) Disinfection and sterilization: After washing the amniotic membrane with normal saline, soak it in aqueous hydrogen peroxide solution for 2-3 hours, and then clean it with water; soak the sterilized amniotic membrane in an aqueous solution containing antibiotics for 2-3 hours;
(2)分阶段真空冷冻干燥:将步骤(1)得到的羊膜置于5~10g/L的海藻酸钠和1~5g/L透明质酸溶液中静置10~15h后,进行真空冷冻干燥,先在2~5℃下预冻2~3h,然后降温到-10~-15℃,冷冻3~5h,在继续降温到-20~-25℃,冷冻3~5h,在继续降温到-40~-50℃,冷冻7~10h,控制羊膜的水分含量在5~10%;(2) Vacuum freeze-drying in stages: place the amniotic membrane obtained in step (1) in a solution of 5-10 g/L sodium alginate and 1-5 g/L hyaluronic acid, let it stand for 10-15 hours, and then carry out vacuum freeze-drying , first pre-freeze at 2-5°C for 2-3 hours, then cool down to -10-15°C, freeze for 3-5 hours, continue to cool down to -20-25°C, freeze for 3-5 hours, and continue to cool down to - 40~-50℃, freeze for 7~10 hours, control the water content of the amniotic membrane at 5~10%;
(3)浸渍中药:将步骤(2)得到的羊膜浸渍在中药提取物中,加热使浸泡温度在30~50℃,浸泡时间为10~15h;其中所述的中药提取物通过以下方法制备得到:按以下质量份取中药药材,大青叶8-10份、蛇床子3-5份、三七3-5份、黄芩1-5份、蒲公英1-3份、野菊花2-3份、金银花1-3份、骨丹3-5份、七里单6-8份、乳香2-3份、没药5-10份、丁香2-5份、红花1-3份、大黄3-5份、甘草3-5份、苍术1-2份,加水煎煮1-2小时,得到的煎煮液经超滤和纳滤后,得到中药精制液,然后加入医用酒精和水混合,调节溶液中酒精浓度为65-70%,并加热至60-70℃得到所述的中药提取物;(3) Soaking Chinese medicine: soak the amniotic membrane obtained in step (2) in the Chinese medicine extract, heat to make the soaking temperature 30-50°C, and the soaking time is 10-15h; wherein the Chinese medicine extract is prepared by the following method : Take Chinese medicinal materials according to the following parts by mass, 8-10 parts of Daqingye, 3-5 parts of Fructus Cnidii, 3-5 parts of Panax notoginseng, 1-5 parts of Scutellaria baicalensis, 1-3 parts of dandelion, 2-3 parts of wild chrysanthemum, Honeysuckle 1-3 parts, Gudan 3-5 parts, Qili Dan 6-8 parts, frankincense 2-3 parts, myrrh 5-10 parts, cloves 2-5 parts, safflower 1-3 parts, rhubarb 3-5 parts 3-5 parts of licorice, 1-2 parts of atractylodes rhizome, add water and decoct for 1-2 hours, the obtained decoction is subjected to ultrafiltration and nanofiltration to obtain the refined liquid of traditional Chinese medicine, and then add medical alcohol and water to mix to adjust the solution The alcohol concentration is 65-70%, and heated to 60-70°C to obtain the Chinese medicine extract;
(4)真空干燥:将步骤(3)处理后的羊膜进行真空干燥处理,温度为60~70℃,干燥时间2-4小时;(4) Vacuum drying: the amniotic membrane treated in step (3) is vacuum-dried at a temperature of 60-70° C., and the drying time is 2-4 hours;
(5)封装灭菌:经过真空干燥后的羊膜进行包装、灭菌即可在常温下保存。(5) Encapsulation and sterilization: the amniotic membrane after vacuum drying is packaged and sterilized to be stored at room temperature.
在本发明的优选的实施方案中,所述过氧化氢水溶液的浓度为2~4g/L。In a preferred embodiment of the present invention, the concentration of the aqueous hydrogen peroxide solution is 2-4 g/L.
在本发明的优选的实施方案中,所述的抗生素选自青霉素、链霉素、庆大霉素中的一种或是两种,其用量分别为50μg/mL、30μg/mL、10μg/mL;In a preferred embodiment of the present invention, the antibiotics are selected from one or both of penicillin, streptomycin, and gentamicin, and the dosages are 50 μg/mL, 30 μg/mL, and 10 μg/mL, respectively. ;
在本发明的优选的实施方案中,所述步骤(4)的真空度为0.01-0.05MPa。In a preferred embodiment of the present invention, the degree of vacuum in step (4) is 0.01-0.05 MPa.
本发明制备的医用敷料可以广泛应用于各种不同程度的创面的治疗,与现有技术相比,本发明具备以下有益效果:The medical dressing prepared by the present invention can be widely used in the treatment of various degrees of wounds. Compared with the prior art, the present invention has the following beneficial effects:
(1)经过长期试验研究,发现采用分阶段的真空冷冻干燥技术,将羊膜在逐级降低的温度下冷冻干燥,阶梯式降温,能够最大程度的保留了其胶原和活性因子成分,使得羊膜的组成没有受到破坏,经检测,所制得的医用敷料含有Ⅰ型胶原290.1±1.0μg/mg、Ⅲ型胶原356.8±2.0μg/mg,Ⅳ型胶原47.1±1.0μg/mg,肝细胞生长因子71.2±1.0μg/mg,碱性成纤维细胞生长因子56.1±1.0μg/mg;而新鲜羊膜中含Ⅰ型胶原303.5±5.3μg/mg,Ⅲ型胶原384.2±4.5μg/mg,Ⅳ型胶原53.6±1.7μg/mg,肝细胞生长因子89.9±3.2μg/mg,碱性成纤维细胞生长因子71.1±1.0μg/mg。(1) After long-term experimental research, it was found that the use of staged vacuum freeze-drying technology, the amniotic membrane is freeze-dried at a gradually lowered temperature, and the stepwise cooling can retain its collagen and active factor components to the greatest extent, making the amniotic membrane more stable. The composition is not damaged. After testing, the prepared medical dressing contains 290.1±1.0 μg/mg of type I collagen, 356.8±2.0 μg/mg of type III collagen, 47.1±1.0 μg/mg of type IV collagen, and 71.2 μg/mg of hepatocyte growth factor ±1.0μg/mg, basic fibroblast growth factor 56.1±1.0μg/mg; and fresh amniotic membrane contains type Ⅰ collagen 303.5±5.3 μg/mg, type Ⅲ collagen 384.2±4.5 μg/mg, type Ⅳ collagen 53.6± 1.7μg/mg, hepatocyte growth factor 89.9±3.2μg/mg, basic fibroblast growth factor 71.1±1.0μg/mg.
(2)通过浸渍本发明的特定中药配方,使得得到的羊膜敷料能够更有效的止血止痛、促进愈合,并且对人体无副作用,使用安全。(2) By impregnating the specific traditional Chinese medicine formula of the present invention, the obtained amniotic membrane dressing can more effectively stop bleeding, relieve pain, and promote healing, and has no side effects on the human body, and is safe to use.
(3)本发明的制备方法简单易行,成本低,无污染。(3) The preparation method of the present invention is simple, easy to implement, low in cost and non-polluting.
具体实施方式detailed description
以下结合实例对本发明技术方案及其效果作进一步的说明。The technical solutions of the present invention and their effects are further described below in conjunction with examples.
实施例1Example 1
(1)消毒杀菌:用生理盐水清洗羊膜后,浸泡于2g/L过氧化氢水溶液中2h,然后用水清洗干净;将消毒后的羊膜浸泡于含有50μg/mL青霉素的水溶液3h;(1) Disinfection and sterilization: After cleaning the amniotic membrane with physiological saline, soak it in 2g/L hydrogen peroxide aqueous solution for 2 hours, and then wash it with water; soak the sterilized amniotic membrane in an aqueous solution containing 50 μg/mL penicillin for 3 hours;
(2)分阶段真空冷冻干燥:将步骤(1)得到的羊膜置于8g/L的海藻酸钠和5g/L透明质酸溶液中静置10h后,进行真空冷冻干燥,先在3℃下预冻3h,然后降温到-10℃,冷冻5h,在继续降温到-20℃,冷冻5h,在继续降温到-50℃,冷冻8h,控制羊膜的水分含量在7%;(2) Vacuum freeze-drying in stages: put the amniotic membrane obtained in step (1) in a solution of 8g/L sodium alginate and 5g/L hyaluronic acid for 10 hours, then carry out vacuum freeze-drying, first at 3°C Pre-freeze for 3 hours, then cool down to -10°C, freeze for 5 hours, continue to cool down to -20°C, freeze for 5 hours, continue to cool down to -50°C, freeze for 8 hours, and control the moisture content of the amniotic membrane at 7%;
(3)浸渍中药:将步骤(2)得到的羊膜浸渍在中药提取物中,加热使浸泡温度在30℃,浸泡时间为15h;其中所述的中药提取物通过以下方法制备得到:按以下质量份取中药药材,大青叶10份、蛇床子3份、三七4份、黄芩2份、蒲公英2份、野菊花2份、金银花2份、骨丹3份、七里单6份、乳香2份、没药6份、丁香3份、红花2份、大黄3份、甘草3份、苍术1份,加水煎煮2小时,得到的煎煮液经超滤和纳滤后,得到中药精制液,然后加入医用酒精和水混合,调节溶液中酒精浓度为70%,并加热至60℃得到所述的中药提取物;(3) Soaking Chinese medicine: soak the amniotic membrane obtained in step (2) in the Chinese medicine extract, heat to make the soaking temperature 30°C, and the soaking time is 15h; wherein the Chinese medicine extract is prepared by the following method: according to the following mass Take Chinese medicinal materials, 10 parts of Daqingye, 3 parts of Cnidium, 4 parts of Panax notoginseng, 2 parts of Scutellaria baicalensis, 2 parts of Dandelion, 2 parts of wild chrysanthemum, 2 parts of honeysuckle, 3 parts of Gu Dan, 6 parts of Qili Dan, 2 parts of frankincense 6 parts of myrrh, 3 parts of cloves, 2 parts of safflower, 3 parts of rhubarb, 3 parts of licorice, 1 part of atractylodes, add water and decoct for 2 hours, and the obtained decoction is subjected to ultrafiltration and nanofiltration to obtain refined Chinese medicine solution, then add medical alcohol and water to mix, adjust the alcohol concentration in the solution to 70%, and heat to 60°C to obtain the Chinese medicine extract;
(4)真空干燥:将步骤(3)处理后的羊膜进行真空干燥处理,真空度为0.02MPa,温度为70℃,干燥时间2小时;(4) Vacuum drying: the amniotic membrane treated in step (3) is subjected to vacuum drying treatment, the vacuum degree is 0.02MPa, the temperature is 70°C, and the drying time is 2 hours;
(5)封装灭菌:经过真空干燥后的羊膜进行包装、灭菌即可在常温下保存。(5) Encapsulation and sterilization: the amniotic membrane after vacuum drying is packaged and sterilized to be stored at room temperature.
经检测,所制得的医用敷料含有Ⅰ型胶原290.1μg/mg、Ⅲ型胶原356.8μg/mg,Ⅳ型胶原47.1μg/mg,肝细胞生长因子71.2μg/mg,碱性成纤维细胞生长因子56.1μg/mg,与新鲜羊膜的成分较为接近,说明上述制备方法基本没有对羊膜的成分造成破坏,极大程度的保持了其原貌。After testing, the prepared medical dressing contained 290.1 μg/mg type I collagen, 356.8 μg/mg type III collagen, 47.1 μg/mg type IV collagen, 71.2 μg/mg hepatocyte growth factor, and 71.2 μg/mg basic fibroblast growth factor 56.1 μg/mg, which is relatively close to the composition of fresh amniotic membrane, indicating that the above preparation method basically does not damage the composition of amniotic membrane, and maintains its original appearance to a great extent.
将制得的医用敷料用于创面,测试其对创面愈合的影响(率,时间)。选用动物的深II度皮肤烫伤模型作为评价敷料对创面愈合影响的动物模型。The prepared medical dressing was used on the wound surface to test its effect on wound healing (rate, time). The animal model of deep second-degree skin burn was selected as the animal model to evaluate the effect of dressing on wound healing.
将雄性Wistar大鼠随机分组,包括自然愈合组、市售常规医用敷料组、本发明医用敷料组,各组观察时相点为伤后3、7、14、21d,每组每时相点10只动物。将大鼠麻醉成功后用80℃水浴烫15秒造成大鼠背部10%深II度皮肤烫伤(病检切片证实),伤后经腹腔给予5ml生理盐水。除自然愈合组外,各组分别用相应敷料覆盖创面。伤后各确定时相点测创面愈合率,先将创面描记在半透明纸上,再以此为模板,将质地均匀的硬纸片剪成同样大小,然后用天平称重,以硬纸片重量间接地表示创面面积大小。按下式计算创面愈合率:创面愈合率(%)=(原始创面面积一未愈合创面面积)/原始创面面积。病理检查,了解创面愈合质量,并根据创面愈合情况确定愈合时间。试验结果显示,本发明医用敷料组,在创面恢复时间上和创面愈合率两方面都优于自然愈合组、市售常规医用敷料组。Male Wistar rats were randomly divided into groups, including the natural healing group, the commercially available conventional medical dressing group, and the medical dressing group of the present invention. only animals. After the rats were successfully anesthetized, scald them in an 80° C. water bath for 15 seconds to cause 10% deep second-degree skin burns on the back of the rats (confirmed by pathological examination sections), and give 5 ml of normal saline through the abdominal cavity after the injury. Except for the natural healing group, each group covered the wound with corresponding dressings. The wound healing rate was measured at each time point after the injury. Firstly, the wound surface was traced on translucent paper, and then as a template, the cardboard with uniform texture was cut into the same size, and then weighed with a balance. The weight indirectly indicates the size of the wound area. The wound healing rate was calculated according to the formula: wound healing rate (%)=(original wound area−unhealed wound area)/original wound area. Pathological examination, to understand the quality of wound healing, and determine the healing time according to the wound healing. The test results show that the medical dressing group of the present invention is superior to the natural healing group and the commercially available conventional medical dressing group in terms of wound recovery time and wound healing rate.
本发明并非限定于所述特定的实施例及说明,并且不脱离在权利要求范围中所请求的本发明的要点,本发明所属的技术领域具有通常知识的人员均可进行各种变形,并且所述变形所属于本发明的保护范围。The present invention is not limited to the specific embodiments and descriptions, and without departing from the gist of the present invention claimed in the scope of the claims, various modifications can be made by those with ordinary knowledge in the technical field to which the present invention belongs, and the The above-mentioned deformation belongs to the protection scope of the present invention.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710189084.1A CN106693034A (en) | 2015-08-03 | 2015-08-03 | Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710189084.1A CN106693034A (en) | 2015-08-03 | 2015-08-03 | Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding |
CN201510468248.5A CN104998294B (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the medical dressing of bactericidal haemostatic |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510468248.5A Division CN104998294B (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the medical dressing of bactericidal haemostatic |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106693034A true CN106693034A (en) | 2017-05-24 |
Family
ID=54371324
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710189024.XA Withdrawn CN106693033A (en) | 2015-08-03 | 2015-08-03 | Preparation method of sterilizing and blooding-stopping medical dressing with low cost |
CN201710189023.5A Withdrawn CN106729935A (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the bactericidal haemostatic medical dressing using safety |
CN201710189022.0A Withdrawn CN106822981A (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the bactericidal haemostatic medical dressing having no side effect |
CN201510468248.5A Active CN104998294B (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the medical dressing of bactericidal haemostatic |
CN201710189084.1A Pending CN106693034A (en) | 2015-08-03 | 2015-08-03 | Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710189024.XA Withdrawn CN106693033A (en) | 2015-08-03 | 2015-08-03 | Preparation method of sterilizing and blooding-stopping medical dressing with low cost |
CN201710189023.5A Withdrawn CN106729935A (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the bactericidal haemostatic medical dressing using safety |
CN201710189022.0A Withdrawn CN106822981A (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the bactericidal haemostatic medical dressing having no side effect |
CN201510468248.5A Active CN104998294B (en) | 2015-08-03 | 2015-08-03 | A kind of preparation method of the medical dressing of bactericidal haemostatic |
Country Status (1)
Country | Link |
---|---|
CN (5) | CN106693033A (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107349335A (en) * | 2017-06-13 | 2017-11-17 | 吉林省拓华生物科技有限公司 | One kind carries medicine membrane film and its production and use |
CZ307603B6 (en) * | 2017-12-27 | 2019-01-02 | BioHealing k.s. | A method for preparing amniotic membrane-based material and a material obtainable by this method |
CN109045143A (en) * | 2018-10-17 | 2018-12-21 | 佛山市妇幼保健院 | A kind of manufacturing method of Chinese medicine perineum ice compress pad |
CN112891062B (en) * | 2021-02-26 | 2022-05-17 | 河南亚都实业有限公司 | A kind of multifunctional nanofiber-based composite hemostatic patch and preparation method thereof |
CN114009541B (en) * | 2021-11-03 | 2024-02-13 | 广西壮族自治区亚热带作物研究所(广西亚热带农产品加工研究所) | Passion fruit tea and processing method thereof |
CN114042185A (en) * | 2021-11-18 | 2022-02-15 | 江苏洁乐医用敷料有限公司 | Preparation method of medical dressing for sterilization and hemostasis |
CN116603092A (en) * | 2023-05-11 | 2023-08-18 | 苏州晟旺新材料科技有限公司 | Self-absorbing antibacterial and healing-promoting medical dressing based on helical fiber structure |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361552A (en) * | 1980-09-26 | 1982-11-30 | Board Of Regents, The University Of Texas System | Wound dressing |
CN1608681A (en) * | 2003-10-17 | 2005-04-27 | 胡杰 | Biological wound dressing |
CN1943796A (en) * | 2006-10-20 | 2007-04-11 | 关志广 | The preparation method of the radiant crosslink porous reticular cells amnionic hydro gel dressing and its preparation method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088118A (en) * | 1992-12-15 | 1994-06-22 | 吕平 | Medical protective tectorial membrane for surfaces of wound |
AUPQ196799A0 (en) * | 1999-08-02 | 1999-08-26 | Pinfold, Ann | Method of preservation of amnion and uses thereof |
WO2007013331A1 (en) * | 2005-07-25 | 2007-02-01 | Arblast Co., Ltd. | Sheet-like composition |
US20140186461A1 (en) * | 2012-09-10 | 2014-07-03 | Alpha Tissue, Inc. | Human Amniotic Membrane Lyophilized Grafts |
-
2015
- 2015-08-03 CN CN201710189024.XA patent/CN106693033A/en not_active Withdrawn
- 2015-08-03 CN CN201710189023.5A patent/CN106729935A/en not_active Withdrawn
- 2015-08-03 CN CN201710189022.0A patent/CN106822981A/en not_active Withdrawn
- 2015-08-03 CN CN201510468248.5A patent/CN104998294B/en active Active
- 2015-08-03 CN CN201710189084.1A patent/CN106693034A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361552A (en) * | 1980-09-26 | 1982-11-30 | Board Of Regents, The University Of Texas System | Wound dressing |
CN1608681A (en) * | 2003-10-17 | 2005-04-27 | 胡杰 | Biological wound dressing |
CN1943796A (en) * | 2006-10-20 | 2007-04-11 | 关志广 | The preparation method of the radiant crosslink porous reticular cells amnionic hydro gel dressing and its preparation method |
Non-Patent Citations (1)
Title |
---|
梁婧等: "人羊膜对创面愈合的促进作用", 《中国美容医学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN106729935A (en) | 2017-05-31 |
CN106693033A (en) | 2017-05-24 |
CN104998294B (en) | 2017-11-14 |
CN104998294A (en) | 2015-10-28 |
CN106822981A (en) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106693034A (en) | Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding | |
CN102091203B (en) | External traditional Chinese medicine preparation for treating refractory wound and preparation method thereof | |
CN106728727A (en) | It is a kind of to treat ointment of sore and preparation method thereof | |
CN108939140A (en) | Composition for hemostasis and medical hemostatic dressing | |
CN101837082B (en) | Chinese preparation for treating burn without leaving scar | |
CN101406589B (en) | Chinese medicine using desiccation exposition method for treating burn | |
CN115998636A (en) | Gel mask containing recombinant humanized collagen and preparation method thereof | |
CN105251040A (en) | Absorbable medical anti-infective suture line and preparation method | |
CN104225258A (en) | Traditional Chinese medicine composition for promoting wound healing | |
CN110507558A (en) | A kind of hyaluronic acid mask liquid for wound repair and preparation method thereof | |
CN105920654A (en) | Burn dressing applicable to department of burn and having antibacterial effect | |
CN113197844A (en) | Scar-free tissue regeneration promoting paste | |
CN108478848A (en) | A kind of antibiotic property medical hemostatic degreasing cotton gauze and preparation method thereof | |
CN114931662B (en) | Skin care dressing and preparation method thereof | |
KR20220105717A (en) | Intraviginal hydrogel composition | |
RU2329822C1 (en) | Antiseptic, anti-inflammatory, analgesic | |
CN116492402B (en) | A Chinese medicine composition for wound repair | |
CN105561382A (en) | Dendrobium officinale liquid woundplast and preparation method thereof | |
CN116726127B (en) | A traditional Chinese medicine gel for repairing wound surface after anal fistula surgery and preparation method thereof | |
CN108355130A (en) | It is a kind of to treat psoriasic temperature sensitive type collagen composite antiphlogistic gel spray and preparation method thereof | |
CN107929382B (en) | Traditional Chinese medicine liquid preparation for repairing postoperative scars | |
CN116036149A (en) | Preparation method and application of nano-scale small molecular fruit nucleic acid ester composite antibacterial gel | |
CN105362675A (en) | Emulsifiable paste for treating plasmacellular mastitis and preparation method thereof | |
CN113144176A (en) | Skin wound repair composition containing plant extract and preparation method thereof | |
ES2908121A1 (en) | Cream for the treatment of ulcers that occur in the skin (Machine-translation by Google Translate, not legally binding) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170524 |
|
WD01 | Invention patent application deemed withdrawn after publication |